The antiviral treatment should be initiated before the development of cirrhosis  

作　　者：Qiao Tang Peng Hu 

机构地区：[1]Department of Infectious Diseases,Institute for Viral Hepatitis,The Key Laboratory of Molecular Biology for Infectious Diseases,Chinese Ministry of Education,The Second Affiliated Hospital of Chongqing Medical University,Chongqing,China

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第1期136-138,共3页肝胆外科与营养（英文）

基　　金：supported in part by grants from the Chongqing Talents Project(No.cstc2021ycjh-bgzxm0150);the First batch of key Disciplines on Public Health in Chongqing,Health Commission of Chongqing,China;the Remarkable Innovation-Clinical Research Project,The Second Affiliated Hospital of Chongqing Medical University;Scientific and Technological Research Program of Chongqing Municipal Education Commission,The Second Affiliated Hospital of Chongqing Medical University(No.KJZD-K202300404).

摘　　要：Hepatitis B virus(HBV)infection increases the risk of liver fibrosis,cirrhosis and hepatocellular carcinoma(HCC)(1).International guidelines recommend antiviral treatment for eligible patients to prevent the development of HCC and the progression of liver disease.However,there is discrepancy in these guidelines regarding treatment recommendations for patients with compensated cirrhosis and low-level viremia(LLV),defined as serum HBV-DNA level of 20-2,000 IU/mL(2-4).And data on the natural history of untreated compensated cirrhotic patients with LLV is limited.

关 键 词：Low-level viraemia maintained virological response(MVR) UNTREATED hepatocellular carcinoma(HCC) decompensated cirrhosis 

分 类 号：R575.2[医药卫生—消化系统]